Results 1 to 10 of about 883,220 (268)

MODELO DE IMPACTO EM SAÚDE PÚBLICA DA INTRODUÇÃO DE UMA VACINA HÉRPES-ZOSTER RECOMBINANTE NO BRASIL

open access: yesBrazilian Journal of Infectious Diseases, 2022
Introdução: O herpes-zoster (HZ) manifesta-se normalmente em idosos ou indivíduos imunocomprometidos a partir da reativação do vírus varicela zoster latente.
Ru Han   +4 more
doaj   +1 more source

Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection

open access: yesnpj Vaccines, 2021
RTS,S/AS01 is an advanced pre-erythrocytic malaria vaccine candidate with demonstrated vaccine efficacy up to 86.7% in controlled human malaria infection (CHMI) studies; however, reproducible immune correlates of protection (CoP) are elusive. To identify
Kelly E. Seaton   +16 more
doaj   +1 more source

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

open access: yesnpj Vaccines, 2022
Vaccination with typhoid conjugate vaccines (TCV) is a major part of typhoid prevention. However, little is known about long-term immune persistence following vaccination with TCVs.
Maria Rosario Capeding   +19 more
doaj   +1 more source

Advances towards licensure of a maternal vaccine for the prevention of invasive group B streptococcus disease in infants: a discussion of different approaches

open access: yesHuman Vaccines & Immunotherapeutics, 2022
Group B streptococcus (Streptococcus agalactiae, GBS) is an important cause of life-threatening disease in newborns. Pregnant women colonized with GBS can transmit the bacteria to the developing fetus, as well as to their neonates during or after ...
Judith Absalon   +6 more
doaj   +1 more source

Vaccine Innovation Conference 2017

open access: yesJournal of Pharmacy & Pharmaceutical Sciences, 2017
Proceedings from the Vaccine Innovation Conference 2017, held May 10, 2017, at Hyatt Regency Hotel, Montréal, QC, Canada, Presented by: Vaccine Industry ...
Vaccine Industry Committee
doaj   +1 more source

Global economic burden per episode for multiple diseases caused by group A Streptococcus

open access: yesnpj Vaccines, 2023
Considering the lack of existing evidence on economic burden for diseases caused by group A Streptococcus, we estimated the economic burden per episode for selected diseases.
Jung-Seok Lee   +4 more
doaj   +1 more source

Effect of maternal separation and transportation stress on the bovine upper respiratory tract microbiome and the immune response to resident opportunistic pathogens

open access: yesAnimal Microbiome, 2021
Background The bovine upper respiratory tract (URT) microbiome includes opportunistic pathogens that cause respiratory disease and stress associated with maternal separation and transportation contributes to the severity of this respiratory disease ...
Nilusha Malmuthuge   +5 more
doaj   +1 more source

Comprehensive Flow Cytometry Analysis of PEI-Based Transfections for Virus-Like Particle Production

open access: yesResearch, 2020
The generation of stable clones for biomolecule production is a common but lengthy and labor-intensive process. For complex molecules, such as viruses or virus-like particles (VLPs), the timeline becomes even more cumbersome. Thus, in the early stages of
Daniel J. Blackstock   +7 more
doaj   +1 more source

Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

open access: yesHuman Vaccines & Immunotherapeutics, 2017
A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a ...
Christopher A. Seid   +15 more
doaj   +1 more source

SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice

open access: yesHuman Vaccines & Immunotherapeutics, 2021
There is an urgent need for an accessible and low-cost COVID-19 vaccine suitable for low- and middle-income countries. Here, we report on the development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed at high levels in yeast (Pichia ...
Jeroen Pollet   +19 more
doaj   +1 more source

Home - About - Disclaimer - Privacy